Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$45.76

1.25 (2.81%)

, TWX

Time Warner

$99.30

-0.49 (-0.49%)

10:50
07/17/17
07/17
10:50
07/17/17
10:50

Einhorn's Greenlight exited Mallinckrodt short bet, Time Warner long

Greenlight Capital's quarterly letter, which was obtained by The Fly, communicates to investors in David Einhorn's fund that Greenlight exited "an unusually large number of positions" in the quarter. Among those, Greenlight said it exited its long positions in IAC (IAC), Time Warner (TWX), and Liberty Global (LBTYA). The firm also said that it had closed its "profitable short position" in Mallinckrodt (MNK). In the letter, Einhorn also discussed the firm's previously disclosed short call on Tesla (TSLA) and long position in General Motors (GM). The firm's five largest equity longs are AerCap (AER), Bayer, CONSOL Energy (CNX), GM and Mylan (MYL), the letter states.

MNK

Mallinckrodt

$45.76

1.25 (2.81%)

TWX

Time Warner

$99.30

-0.49 (-0.49%)

IAC

IAC

$105.36

-0.71 (-0.67%)

LBTYA

Liberty Global

$32.82

0.31 (0.95%)

AER

AerCap

$48.06

0.43 (0.90%)

BAYRY

Bayer

$129.37

0.4 (0.31%)

CNX

CONSOL

$15.97

0.195 (1.24%)

MYL

Mylan

$39.21

0.16 (0.41%)

  • 26

    Jul

  • 27

    Jul

  • 01

    Aug

  • 03

    Aug

  • 08

    Aug

  • 03

    Sep

  • 09

    Oct

MNK Mallinckrodt
$45.76

1.25 (2.81%)

06/29/17
UBSW
06/29/17
NO CHANGE
Target $70
UBSW
Buy
Mallinckrodt sum-of-the-parts still supports $70 price target, says UBS
UBS analyst Marc Goodman said his sum-of-the-parts valuation for Mallinckrodt still supports a $70 price target. The analyst said shares at current price remain attractive with the key overhang being the sustainability of Acthar from competition. Without competition, Goodman believes the shares are worth $100. He sees a favorable risk/reward as management has talked about a sense of urgency in getting the stock moving. Goodman reiterated his Buy rating and $70 price target on Mallinckrodt shares.
06/16/17
CANT
06/16/17
INITIATION
Target $52
CANT
Overweight
Mallinckrodt initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Mallinckrodt with an Overweight rating and $52 price target.
06/20/17
JEFF
06/20/17
NO CHANGE
Target $70
JEFF
Buy
Jefferies sees $60-$75 per share buyout range for Mallinckrodt
Amid speculation that Mallinckrodt is seeking strategic alternatives, Jefferies analyst Anthony Petrone explored leveraged buyout scenarios in order to gauge the feasibility of a sponsor-led transaction. His work shows that within a $60-$75 per share takeout range, sponsors can clear a 30% internal rate of return hurdle under "modest assumptions" with upside to 45%-plus when engineering scenarios are considered. The largest risks to the LBO assumptions are around stability in Acthar pricing and the competitive landscape, Petrone tells investors in a research note. The analyst keeps a Buy rating on Mallinckrodt with a $70 price target. The specialty pharmaceutical company closed yesterday up 5%, or $1.94, to $43.64.
06/21/17
WELS
06/21/17
NO CHANGE
WELS
Outperform
Wells doesn't see Mallinckrodt at significant risk of violating debt covenants
Wells Fargo analyst David Maris believes Mallinckrodt's debt and leverage "seem very manageable" and argues that investors "should not be overly concerned" about the company's potential to violate its debt covenants. In a note issued before the open, Maris characterized Mallinckrodt's covenants as "loose." He keeps an Outperform rating on Mallinckrodt shares.
TWX Time Warner
$99.30

-0.49 (-0.49%)

05/03/17
05/03/17
DOWNGRADE

Hold
Wunderlich downgrades Charter on valuation, sees some level of M&A priced in
As previously reported, Wunderlich analyst Matthew Harrigan downgraded Charter (CHTR) to Hold from Buy, citing valuation. He thinks that the current stock price imbeds some expectation for merger activity, apart from an eventual collapse of the Liberty Broadband (LBRDA) and Liberty Ventures (LVNTA) ownership structure, he tells investors. While a theoretical merger with Verizon (VZ) is "at least as strategically compelling" as AT&T's (T) deal for Time Warner (TWX), Harrigan thinks that price and regulatory hurdles could be difficult to overcome. He cut his price target on Charter to $350 from $360.
04/24/17
OPCO
04/24/17
NO CHANGE
OPCO
Sprint, DISH the only assets for sale, says Oppenheimer
Oppenheimer analyst Timothy Horan noted that wireless companies will be allowed to discuss M&A, and says he sees Sprint (S) and possibly DISH (DISH) as the only assets for sale. The analyst believes the most likely outcome is for consolidation around the four major wireless providers, something along the lines of Charter (CHTR)/Sprint, T-Mobile (TMUS)/Comcast (CMCSA; CMCSK), Verizon (VZ)/DISH, with AT&T's (T) position "fairly solidified" with DirectTV/Time Warner (TWX). Further, Horan suspects Sprint will be sold first, most likely to Charter, although T-Mobile is a possibility and could be the controlling company/management and likely paying a premium for Sprint.
04/20/17
04/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) downgraded to Peer Perform from Outperform at Wolfe Research with analyst Scott Mushkin saying shares are approaching his price target and he expects increasing competition through year-end. 2. Time Warner (TWX) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying shares are trading near the value of AT&T's (T) offering price. 3. Molson Coors (TAP) downgraded to Market Perform from Outperform at Cowen with analyst Vivien Azer citing expectations for persistent beer volume headwinds. The analyst believes alcohol consumption could be pressured for at least the next decade, partly due to increased cannabis use, and a contraction in the alcohol cycle. Azer said Molson is uniquely exposed to the increasingly vibrant and growing cannabis markets and notes there is an inverse relationship between cannabis use and alcohol consumption over time. 4. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi with analyst James Cakmak saying he sees insufficient upside to estimates to justify the lofty valuation. The analyst said the path to double-digit growth may be pushed out 2019 and limited potential to outperform topline expectations in 2017. Further, the analyst sees margin pressures from product mix towards StubHub and rising development spend for the backend, and limited opportunities for multiple expansion. 5. Ruth's Hospitality (RUTH) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/20/17
PIVT
04/20/17
DOWNGRADE
PIVT
Hold
Time Warner downgraded to Hold from Buy at Pivotal Research
Pivotal Research analyst Brian Wieser downgraded Time Warner (TWX) to Hold saying shares are trading near the value of AT&T's (T) offering price.
IAC IAC
$105.36

-0.71 (-0.67%)

05/26/17
PIPR
05/26/17
NO CHANGE
Target $130
PIPR
Overweight
IAC price target raised to $130 from $111 at Piper Jaffray
Piper Jaffray analyst Samuel Kemp raised his price target for IAC to $130 saying the upcoming close of the Angie's List/ HomeAdvisor deal could put "upward pressure" on the shares. The analyst remains bullish on HomeAdvisor fundamentals and keeps an Overweight rating on IAC.
06/14/17
BOFA
06/14/17
NO CHANGE
Target $133
BOFA
Buy
IAC discounted valuation not sustainable, says BofA/Merrill
BofA/Merrill analyst Nat Schindler believes IAC shares remain undervalued and is trading at a discount to enterprise value based on its ownership in Match and implied cost value of Angie's stock. The analyst also said the company has a high cash balance available for acquisitions and other asset in the portfolio have potential for value creation. Schindler rates IAC a Buy with a $133 price target.
05/08/17
LEHM
05/08/17
NO CHANGE
Target $105
LEHM
Overweight
IAC price target raised to $105 from $96 at Barclays
Barclays analyst Ross Sandler raised his price target for IAC to $105 saying that around $99 per share, Vimeo, apps and the company's cash are not being fully valued. The analyst maintains an Overweight rating on IAC following the Q1 results.
05/09/17
AGIS
05/09/17
NO CHANGE
Target $115
AGIS
Buy
IAC price target raised to $115 from $86 at Aegis
Aegis analyst Victor Anthony raised IAC's price target to $115 from $86 to reflect the "unlocked value" of the Angie's List Homeservices business. The analyst believes the combination of HomeAdvisor and Angie's List will accelerate the adoption of the home services market given management's strong understanding of the business, having driven 30% topline growth at HomeAdvisor in the domestic market for 9 consecutive quarters. Anthony rates IAC a Buy.
LBTYA Liberty Global
$32.82

0.31 (0.95%)

06/16/17
UBSW
06/16/17
INITIATION
Target $31
UBSW
Neutral
Liberty Global initiated with a Neutral at UBS
UBS analyst Polo Tang started Liberty Global (LBTYA) with a Neutral rating and $31 price target. The analyst, while admitting the stock's risk/reward "is becoming more attractive," prefers to await a better entry point. Tang looked at potential M&A upside from a deal with Vodafone (VOD), and says upside is "potentially significant." He believes a combination with Vodafone could yield synergies of $12-$16 per Liberty Global share, but adds a deal "is not necessarily imminent."
05/24/17
FBCO
05/24/17
DOWNGRADE
Target $30
FBCO
Neutral
Liberty Global downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Henrik Herbst downgraded Liberty Global to Neutral and lowered his price target for the shares to $30 from $42. After years of price increases, European broadband customers are starting to resist further raises, Herbst tells investors in a research note. The longer-term strategic outlook for cable in Europe is also slowly deteriorating, the analyst adds.
05/15/17
SBSH
05/15/17
NO CHANGE
Target $40
SBSH
Buy
Liberty Global pullback brings attractive entry point, says Citi
Citi analyst Simon Weeden views the post-earnings selloff in shares of Liberty Global as creating an attractive entry point. The analyst continues to see potential for "strong" free cash flow following the new build investment phase and for value creating M&A both as an acquirer and target. He keeps a Buy rating on Liberty Global with a $40 price target.
01/23/17
01/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Liberty Global (LBTYA) resumed with an Equal Weight at Morgan Stanley. 2. BioMarin (BMRN) and Incyte (INCY) were initiated with an Outperform at Credit Suisse. 3. GrubHub (GRUB) initiated with a Hold at Craig-Hallum. 4. Molson Coors (TAP) initiated with a Neutral at Credit Suisse. 5. Achaogen (AKAO) initiated with a Buy at Guggenheim. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AER AerCap
$48.06

0.43 (0.90%)

01/04/17
COMP
01/04/17
INITIATION
Target $60
COMP
Buy
AerCap initiated with a Buy at Compass Point
Compass Point analyst Scott Valentin initiated AerCap with a Buy and a $60 price target. The analyst said AerCap has a high level of earnings visibility given the robust order book and high percentage of future deliveries placed, high level of profitability as evidenced by strong profit margin and relatively high ROE; and is best positioned among lessors to benefit from a reduction in the corporate tax rate.
01/04/17
COMP
01/04/17
INITIATION
Target $60
COMP
Buy
AerCap initiated with a Buy at Compass Point
Compass Point analyst Scott Valentin initiated AerCap with a Buy and a $60 price target.
04/06/17
MSCO
04/06/17
DOWNGRADE
MSCO
Equal Weight
AerCap downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani downgraded AerCap to Equal Weight and lowered his price target to $44 from $48 telling investors shares have had a solid run and faces headwinds from peaking airline profits and order activity.
05/22/17
DADA
05/22/17
NO CHANGE
DADA
AerCap shares should be bought at current levels, says DA Davidson
DA Davidson analyst Arren Cyganovich says that AerCap's stock has reached an attractive entry point. The analyst thinks that the company has "strong growth dynamics," while the stock's current valuation would be low even if the environment became "severely stressed." Cyganovich does not expect the latter scenario to unfold and keeps a $60 price target and Buy rating on the stock.
BAYRY Bayer
$129.37

0.4 (0.31%)

03/03/17
JPMS
03/03/17
NO CHANGE
Target $128
JPMS
Overweight
EU approvals of other ag deals may narrow Monsanto deal spread, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas said commentary from the CEOs of DuPont (DD) and Syngenta (SYT) and press reports from Europe suggest that their deals with Dow Chemical (DOW) and ChemChina, respectively, are likely to be approved. Approvals from Europe for those deals may "trigger a meaningful closing of the arbitrage spread" in Monsanto (MON) shares versus Bayer's (BAYRY) offer price, Zekauskas tells investors. He recommends buying Monsanto shares at current levels for this reason, adding that he believes the shares would only fall about 2.5%, or down to $112, in the event of the Bayer deal falling through. Zekauskas keeps an Overweight rating and $128 price target on Monsanto shares, which closed yesterday at just below $115 per share.
04/06/17
JPMS
04/06/17
NO CHANGE
Target $128
JPMS
Overweight
Monsanto shares offer 'excellent' risk/reward proposition, says JPMorgan
JPMorgan analyst Jeffrey Zekauskas says shares of Monsanto (MON) at current levels offer an "excellent" risk/reward proposition. The analyst views capital appreciation potential to the end of 2017 as 11% or a 15% annual return. He sees downside risk of only 3%, to $112 per share, in the event that Bayer (BAYRY) is not able to consummate the acquisition. Zekauskas has increased confidence in the deal closing following recent regulatory rulings and keeps an Overweight rating on the name with a $128 price target.
04/10/17
PIPR
04/10/17
NO CHANGE
Target $17
PIPR
Overweight
OncoMed price target lowered to $17 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for OncoMed (OMED) to $17 from $26 following two negative announcements, namely that the Phase II YOSEMITE study of demcizumab in first line pancreatic cancer failed and Bayer (BAYRY) returned rights for ipafricept and vantictumab. The analyst also notes that now partner Celgene (CELG) will review all data on demcizumab including Phase II DENALI non-small cell lung cancer data and Phase Ib combo data with KEYTRUDA, although he does not expect Celgene to exercise its option. Tenthoff reiterates an Overweight rating on OncoMed's shares.
06/27/17
SUSQ
06/27/17
DOWNGRADE
Target $128
SUSQ
Neutral
Monsanto downgraded to Neutral at Susquehanna
As previously reported, Susquehanna analyst Don Carson downgraded Monsanto (MON) to Neutral from Positive. The downgrade reflects the 9% upside to the $128 price target offer from Bayer (BAYRY), which is less than the firm's 15% threshold for a Positive rating. The companies expects the deal to close by calendar year-end 2017.
CNX CONSOL
$15.97

0.195 (1.24%)

12/09/16
GSCO
12/09/16
INITIATION
Target $21
GSCO
Neutral
CONSOL initiated with a Neutral at Goldman
Goldman analyst John Nelson initiated CONSOL with a Neutral and a $21 price target.
12/09/16
12/09/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chesapeake Utilities (CPK) initiated with a Neutral at Ladenburg. 2. CONSOL (CNX) initiated with a Neutral at Goldman. 3. Johnson Controls (JCI) assumed with an Equal Weight at Barclays. 4. American Midstream Partners (AMID) initiated with a Buy at Janney Capital. 5. Brookfield Infrastructure (BIP) coverage resumed with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/17
RHCO
01/30/17
DOWNGRADE
RHCO
Hold
CONSOL downgraded to Hold from Buy at SunTrust
01/30/17
01/30/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Colgate-Palmolive (CL) downgraded to Neutral from Buy at Citi with analyst Wendy Nicholson saying the sales the "breadth of the top-line weakness" in the company's fourth quarter results is "very disconcerting." Even with the 5% post-earnings pullback, Colgate shares are still not cheap, Nicholson tells investors in a research note. She lowered her price target for the shares to $70 from $76. 2. Air Products (APD) downgraded to Neutral from Outperform at Baird with analyst David Manthey saying he believes the catalyst that led to identifiable margin improvement last quarter may have substantially played out and the company is now more exposed to sluggish economic trends that have underpinned his cautious thinking on Praxair (PX). Manthey lowered his price target to $140 from $146 on Air Products shares. 3. Barclays (BCS) downgraded to Sell from Hold at Berenberg with analyst Peter Richardson citing valuation and high investment banking expectations reflected in shares. 4. Symantec (SYMC) reinstated with a Neutral from Buy at Citi with analyst Walter Pritchard downgrading Symantec (SYMC) to Neutral from Buy after reinstating coverage of the name. The analyst sees "weaker strategic merit" in the company's LifeLock (LOCK) acquisition relative to the Blue Coat deal. He also believes success is being priced in with investors looking for $2.00-plus in earnings power. Pritchard raised his price target for Symantec shares to $29 from $26.50. 5. CONSOL (CNX) downgraded to Hold from Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MYL Mylan
$39.21

0.16 (0.41%)

05/31/17
WELS
05/31/17
NO CHANGE
WELS
Market Perform
Pension fund campaign a short-term negative for Mylan, says Wells Fargo
Wells Fargo analyst David Maris believes the campaign by four major pension funds to oppose the re-election of six directors is short-term negative for Mylan but has the potential to be a longer term positive. The campaign may pose a distraction to management, but if successful, it could address some governance concerns regarding compensation and performance at the company, Maris tells investors in a research note. The analyst has a Market Perform rating on Mylan shares.
06/12/17
SBSH
06/12/17
NO CHANGE
Target $38
SBSH
Buy
Citi says CRL for Coherus not worst case scenario
Citi analyst Mohit Bansal says Coherus Biosciences' (CHRS) complete response letter for its biosimilar version of Neulasta, while "clearly a negative outcome," is not the worst case scenario since the FDA did not ask for another study. The analyst sees a one year delay, which impacts his discounted free cash flow model by $5 per share. Coherus in premarket trading is down 30%, or $6.25, to $14.40. A one year delay would mean Coherus' CHS-1701 could still be on markets at the same time as competition from Mylan (MYL) and ahead of Sandoz's approval in 2019, Bansal tells investors in a research note. The analyst has a Buy rating on Coherus with a $38 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $41
CANT
Neutral
Mylan initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Mylan with a Neutral rating and $41 price target.
06/21/17
WELS
06/21/17
NO CHANGE
WELS
Market Perform
Wells wouldn't be surprised to see greater scrutiny on Mylan coal tax credits
After a new report from Reuters questioned the way in which Mylan uses its ownership of coal processing plants to keep its taxes low, Wells Fargo analyst David Maris said this topic has interested him for some time but his questions to management on the issue were not answered. Maris, who said he would not be surprised to see greater public scrutiny on this issue after the report, keeps a Market Perform rating on Mylan shares.

TODAY'S FREE FLY STORIES

EGRX

Eagle Pharmaceuticals

$70.04

-2.76 (-3.79%)

12:37
07/26/17
07/26
12:37
07/26/17
12:37
Hot Stocks
Breaking Hot Stocks news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

EGRX

Eagle Pharmaceuticals

$70.04

-2.76 (-3.79%)

12:36
07/26/17
07/26
12:36
07/26/17
12:36
Hot Stocks
Breaking Hot Stocks news story on Eagle Pharmaceuticals »

Eagle says FDA asks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

CMG

Chipotle

$346.19

-2.427 (-0.70%)

12:36
07/26/17
07/26
12:36
07/26/17
12:36
Periodicals
Expert calls Chipotle's FDA criminal subpoena 'highly unusual,' NY Post reports »

The subpoena from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGRX

Eagle Pharmaceuticals

$70.04

-2.76 (-3.79%)

12:36
07/26/17
07/26
12:36
07/26/17
12:36
Hot Stocks
Eagle Pharmaceuticals receives complete response letter from FDA on Ryanodex »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

IVPAF

Ivanhoe Mines

$3.89

0.1263 (3.36%)

12:33
07/26/17
07/26
12:33
07/26/17
12:33
Conference/Events
Ivanhoe Mines management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

WYNN

Wynn Resorts

$138.98

0.45 (0.32%)

12:30
07/26/17
07/26
12:30
07/26/17
12:30
Options
Wynn Resorts calls active as shares fall on earnings »

Wynn Resorts calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGRX

Eagle Pharmaceuticals

$70.04

-2.76 (-3.79%)

12:29
07/26/17
07/26
12:29
07/26/17
12:29
Hot Stocks
Breaking Hot Stocks news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FLY

Fly Leasing

$13.94

-0.04 (-0.29%)

12:27
07/26/17
07/26
12:27
07/26/17
12:27
Conference/Events
Fly Leasing management to meet with RBC Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 10

    Aug

SIRI

SiriusXM

$5.39

0.01 (0.19%)

12:25
07/26/17
07/26
12:25
07/26/17
12:25
Options
Sirius XM call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 05

    Sep

AKAM

Akamai

$53.28

0.91 (1.74%)

12:24
07/26/17
07/26
12:24
07/26/17
12:24
Conference/Events
Akamai management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

  • 08

    Aug

  • 05

    Sep

MPC

Marathon Petroleum

$56.44

0.42 (0.75%)

12:20
07/26/17
07/26
12:20
07/26/17
12:20
Hot Stocks
Marathon Petroleum raises quarterly dividend 11% to 40c per share »

Marathon Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

$NSD

NASDAQ Market Internals

12:17
07/26/17
07/26
12:17
07/26/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
07/26/17
07/26
12:16
07/26/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSCO

Tractor Supply

$53.53

2.01 (3.90%)

12:15
07/26/17
07/26
12:15
07/26/17
12:15
Options
Tractor Supply put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

BA

Boeing

$230.75

18.29 (8.61%)

, KO

Coca-Cola

$45.36

0.1151 (0.25%)

12:03
07/26/17
07/26
12:03
07/26/17
12:03
General news
On The Fly: Top stock stories at midday »

Stocks opened in positive…

BA

Boeing

$230.75

18.29 (8.61%)

KO

Coca-Cola

$45.36

0.1151 (0.25%)

T

AT&T

$37.84

1.62 (4.47%)

AMD

AMD

$14.11

-0.05 (-0.35%)

TXN

Texas Instruments

$81.39

0.47 (0.58%)

GLW

Corning

$30.29

-1.84 (-5.73%)

GD

General Dynamics

$194.50

-9.06 (-4.45%)

AMGN

Amgen

$180.89

-0.17 (-0.09%)

IRBT

iRobot

$87.90

-2.48 (-2.74%)

AMED

Amedisys

$59.41

0.61 (1.04%)

AFAM

Almost Family

$56.70

-0.15 (-0.26%)

HLS

HealthSouth

$43.48

-2.24 (-4.90%)

KND

Kindred Healthcare

$9.70

-1.5 (-13.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

  • 30

    Jul

  • 01

    Aug

  • 04

    Aug

  • 07

    Aug

  • 08

    Aug

  • 14

    Aug

  • 14

    Aug

  • 15

    Aug

  • 16

    Aug

  • 17

    Aug

  • 23

    Aug

  • 23

    Aug

  • 29

    Aug

  • 07

    Sep

  • 08

    Sep

  • 14

    Sep

  • 16

    Nov

  • 03

    Feb

  • 17

    May

GSM

Ferroglobe

$12.90

0.32 (2.54%)

12:02
07/26/17
07/26
12:02
07/26/17
12:02
Hot Stocks
Ferroglobe has not received regulatory approvals from Spain's water authority »

Ferroglobe announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

MNGA

Magnegas

$0.75

-0.1699 (-18.47%)

12:01
07/26/17
07/26
12:01
07/26/17
12:01
Hot Stocks
USPTO issues MagneGas patent on MagneCule theory »

MagneGas Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$22.77

0.01 (0.04%)

12:00
07/26/17
07/26
12:00
07/26/17
12:00
Options
Post-earnings option play opened in JetBlue »

Post-earnings option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

BA

Boeing

$229.65

17.1924 (8.09%)

11:54
07/26/17
07/26
11:54
07/26/17
11:54
Hot Stocks
Boeing seeing Pentagon demand above Trump's FY18 budget request »

In its Defense, Space…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

WY

Weyerhaeuser

$34.11

-0.014 (-0.04%)

11:50
07/26/17
07/26
11:50
07/26/17
11:50
Options
Call buyer in Weyerhaeuser ahead of earnings »

Call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

LVMUY

LVMH

$51.12

-0.02 (-0.04%)

11:49
07/26/17
07/26
11:49
07/26/17
11:49
Earnings
LVMH reports first half revenue up 15% to EUR 19.7B »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$229.61

17.15 (8.07%)

11:47
07/26/17
07/26
11:47
07/26/17
11:47
Hot Stocks
Boeing has over '700 firm orders in backlog' for 787 Dreamliner program »

Boeing said its 787…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

FB

Facebook

$165.28

-0.72 (-0.43%)

11:45
07/26/17
07/26
11:45
07/26/17
11:45
Technical Analysis
Technical Earnings Preview: Facebook in strong uptrend before news »

The stock has been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 13

    Sep

CF

CF Industries

$29.01

-1.16 (-3.84%)

11:45
07/26/17
07/26
11:45
07/26/17
11:45
Options
CF Industries call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

11:45
07/26/17
07/26
11:45
07/26/17
11:45
General news
Treasury's $15 B 2-year FRN garnered decent results »

Treasury's $15 B…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.